Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

BACKGROUND: There is need for well-tolerated therapies for prostate cancer (PrCa) secondary prevention and to improve response to radiotherapy (RT). The anti-diabetic agent metformin (MET) and the aspirin metabolite salicylate (SAL) are shown to activate AMP-activated protein kinase (AMPK), suppress...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsakiridis, Evangelia E., Broadfield, Lindsay, Marcinko, Katarina, Biziotis, Olga-Demetra, Ali, Amr, Mekhaeil, Bassem, Ahmadi, Elham, Singh, Kanwaldeep, Mesci, Aruz, Zacharidis, Panayiotis G., Anagnostopoulos, Alexander E., Berg, Tobias, Muti, Paola, Steinberg, Gregory R., Tsakiridis, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411238/
https://www.ncbi.nlm.nih.gov/pubmed/34479029
http://dx.doi.org/10.1016/j.tranon.2021.101209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411238/
https://www.ncbi.nlm.nih.gov/pubmed/34479029
http://dx.doi.org/10.1016/j.tranon.2021.101209

Ejemplares similares